I. INTRODUCTION ................................................................. 1

II. PREVIOUS LITERATURE

Tests for evaluation of antimalarial activity
a. Blood schizontocidal activity ........................................ 6
b. Tissue schizontocidal activity ........................................... 7
c. Activity after single dose treatment .................................. 8

Hosts for Plasmodium berghei ................................................. 9
Criteria for antimalarial activity against blood forms in P.berghei - mouse model .................................................. 10

Drug resistance .............................................................. 12

Pyrimethamine resistance in experimental studies. 16
Chloroquine resistance in experimental studies. 17
Primaquine resistance in experimental studies. 18
Mefloquine resistance in experimental studies. 18

III. MATERIAL AND METHODS

Maintenance of laboratory infections ...................................... 19

Drugs and antibiotics .......................................................... 21

Experimental studies
a. Selection of host ............................................................ 22
b. Chemotherapeutic studies

(i) Blood schizontocidal activity ......................................... 23
(ii) Tissue schizontocidal activity ......................................... 24
(iii) Activity after single dose treatment ................................ 25

Studies on drug resistance
a. Selection of resistant strain ............................................. 25
b. Stability of resistance ..................................................... 26
c. Sensitivity of the resistant strain to other antimalarial drugs and antibiotics ................................................. 26
IV. OBSERVATIONS

A. Chemotherapy

Studies with asexual erythrocytic stages of *P. berghei*

a. Standardization of model  ...  ...  ...  27
b. Criteria for assessment of antimalarial activity  ...  ...  ...  ...  ...  28
c. Activity after single dose treatment  ...  ...  ...  ...  ...  30

Studies with tissue stages of *P. gallinaceum*

Standardization of model for chemoprophylaxis  32
Chemoprophylactic activity of pyrimethamine  32
Chemoprophylactic activity of primaquine, mefloquine and antibiotics  ...  ...  ...  33

B. Drug Resistance

Pyrimethamine resistant *P. berghei*  ...  ...  ...  34
Chloroquine resistant *P. berghei*  ...  ...  ...  37
Primaquine resistant *P. berghei*  ...  ...  ...  39
Mefloquine resistant *P. berghei*  ...  ...  ...  40

V. DISCUSSION

A. Chemotherapy

Studies with asexual erythrocytic stages of *P. berghei*

a. Standardization of model  ...  ...  ...  42
b. Schizontocidal activity of known and new antimalarial drugs and antibiotics in *P. berghei*.  ...  ...  ...  ...  ...  43
c. Activity of drugs after single dose treatment.  ...  ...  ...  ...  ...  47

Studies with tissue stages of *P. gallinaceum*

Chemoprophylaxis with pyrimethamine, primaquine, mefloquine and antibiotics  ...  ...  ...  48
# B. Drug Resistance

<table>
<thead>
<tr>
<th>Strain</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrimethamine resistant strain</td>
<td>51</td>
</tr>
<tr>
<td>Chloroquine resistant strain</td>
<td>52</td>
</tr>
<tr>
<td>Primaquine resistant strain</td>
<td>53</td>
</tr>
<tr>
<td>Mefloquine resistant strain</td>
<td>56</td>
</tr>
</tbody>
</table>

## SUMMARY

Page 59

## BIBLIOGRAPHY

Page 66